News stories about Minerva Neurosciences (NASDAQ:NERV) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Minerva Neurosciences earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.5703761635905 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- Minerva Neurosciences (NERV) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS (americanbankingnews.com)
- Edited Transcript of NERV earnings conference call or presentation 3-May-18 12:30pm GMT (finance.yahoo.com)
- Minerva Neurosciences’ (NERV) CEO Dr. Remy Luthringer on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Minerva Neurosciences: 1Q Earnings Snapshot (finance.yahoo.com)
- Minerva Neurosciences (NERV) Raised to Sell at ValuEngine (americanbankingnews.com)
Shares of NERV stock traded down $0.10 on Tuesday, reaching $6.10. 167,400 shares of the company were exchanged, compared to its average volume of 174,442. The stock has a market capitalization of $240.25 million, a P/E ratio of -5.65 and a beta of 1.43. Minerva Neurosciences has a 1 year low of $4.80 and a 1 year high of $11.15.
Minerva Neurosciences (NASDAQ:NERV) last released its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). equities research analysts expect that Minerva Neurosciences will post -1.46 earnings per share for the current year.
A number of research analysts have weighed in on the stock. ValuEngine raised shares of Minerva Neurosciences from a “strong sell” rating to a “sell” rating in a report on Wednesday, April 4th. BidaskClub raised shares of Minerva Neurosciences from a “hold” rating to a “buy” rating in a report on Friday, April 6th. Finally, Zacks Investment Research raised shares of Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $7.25 price objective for the company in a report on Friday, March 16th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. Minerva Neurosciences presently has an average rating of “Buy” and an average price target of $12.75.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.